ライフサイエンスコーパス: IC50

1 IC50 values for (S)-orteronel were identical for blockin

2 IC50 values of the hydrolysates were between 27 and 39mg

3 IC50 values were 0.22 +/- 0.09 nM for Y537S-ER (P = 0.97

4 VU590 also inhibits Kir7.1 (IC50 approximately 8 muM), and has been used to reveal n

5 mol/L) and IK1 (HEK cells expressing Kir2.1, IC50=44+/-3 mumol/L).

6 32 nM; 3b, IC50 approximately 9 nM; and 14, IC50 approximately 35 nM) inhibit ATX-dependent invasion

7 uctures of the most potent hit (compound 19, IC50 = 2.9 muM) in complex with the enzyme.

8 , risedronate (IC50 > 100 muM) or GGTI-2133 (IC50 > 25 muM) inhibited the growth of ovarian cancer ce

9 th BRCA2 and TP53 wild type) and MDA-MB-231 (IC50 = 7.9 muM, BRCA2 wild type but TP53 mutant).

10 xypyridin-3-yl)methyl)-3-phenylisoxazole 25 (IC50 = 2 nM, 14-fold selectivity over CYP11B2), exhibiti

11 he results demonstrated that T. daenensis-3 (IC50=273.36), T. vulgaris (IC50=289.3), and T. fedtschen

12 ulgaris (IC50=289.3), and T. fedtschenkoi-3 (IC50=339.22) possessed higher antioxidant activities tha

13 5-methyl-3-phenylisoxazole-4-carboxamide (3, IC50 = 3 muM), exhibited no activity on the protein kina

14 f 8TQ yielded a small molecule compound (35, IC50 value approximately 400 nM) that is a potent and se

15 Inhibitor 36 (IC50 = 80 nM) was identified to be highly selective for

16 The three most potent analogues (3a, IC50 approximately 32 nM; 3b, IC50 approximately 9 nM; a

17 analogues (3a, IC50 approximately 32 nM; 3b, IC50 approximately 9 nM; and 14, IC50 approximately 35 n

18 Two of the most potent compounds, 3b and 3f (IC50 approximately 84 nM), lack inhibitory action on ENP

19 ound 21b, a potent inhibitor of Clk1 and -4 (IC50 = 7 and 2.3 nM, respectively), exhibiting an unprec

20 on needed to suppress palmitate flux by 50% (IC50(palmitate)f).In the omega-3 group, the EPA and DHA

21 The inhibitory concentration 50% (IC50) of NSC319726 was 35-800-fold higher than the Minim

22 t growth, with inhibition concentration 50% (IC50) ranging from 1.6 to 12.0 mg L(-1).

23 beteus nigricolor, potently inhibits NaV1.7 (IC50 0.9 nM) with at least 40-1000-fold selectivity over

24 pyridin-3-yl)methyl)-2-phenylpyridine Ref 7 (IC50= 2 nM) exhibited promutagenic potential as well as

25 s (MBPs) revealed that 8-thioquinoline (8TQ, IC50 value approximately 2.5 muM) displayed strong inhib

26 ivity on L-type calcium channels, i.e. A7r5 (IC50 = 0.18 +/- 0.02 and 0.25 +/- 0.63 mug/ml, respectiv

27 had the highest ACE inhibitory activity (ACE IC50=5.21+/-0.94muM).

28 0.14muM which was better than ascorbic acid (IC50=22.59+/-0.30muM).

29 statin (IC50 = 0.6-14 muM), zoledronic acid (IC50 = 21-57 muM), risedronate (IC50 > 100 muM) or GGTI-

30 umol peptide) and ACE inhibitory activities (IC50=44-120muM).

31 sing compounds such as DRI-C21045, activity (IC50) in the low micromolar range has been confirmed in

32 24 displayed excellent inhibitory activity (IC50 of 0.82 +/- 0.18 muM and 1.3 +/- 0.22 muM, respecti

33 anced alpha-glucosidase inhibitory activity (IC50=6.15mug/mL), with castalagin (7) as the main consti

34 and S473, and inhibited Akt kinase activity (IC50 = 6 microM) and downstream signaling.

35 is supported by its agr-quenching activity (IC50 2-32 mug mL(-1)) in transcriptional reporters, dire

36 PSMA affinities (IC50) and internalization kinetics of (99m)Tc-MAS3-y-nal

37 nly 3 of 97 bound A*0101 with high affinity (IC50 < 500 nM).

38 publicly disclosed, submicromolar-affinity (IC50 = 0.2 muM), small-molecule inhibitor of the inward

39 ty to low concentrations of 4-aminopyridine (IC50 <100 mum) and block by the peptide inhibitor blood

40 d inhibitory activity against alpha-amylase, IC50 0.74+/-0.02mg/ml and 0.81+/-0.03mg/ml, respectively

41 n the RS4;11 leukemia cell line, achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth

42 ne-2-sulfonate (PSB-16133, 61) exhibited an IC50 value of 233 nM, selectivity versus other P2Y recep

43 The most potent compound (ML10) has an IC50 of 160 pM in a PfPKG kinase assay and inhibits P. f

44 ve out of 28 compounds were found to have an IC50 less than 5 muM.

45 Compound 1 turned out to possess an IC50 of 93.7 and of 4.6 nM on MDM2 and MDM4, respectivel

46 ),1-Nal(4),Thr(8)]ghrelin(1-8), possessed an IC50 value of 0.11 nM that is a 28-fold improvement comp

47 Model simulations predicted an IC50 of 1-1.2 mum for SB203580 in hepatocytes.

48 The array showed an IC50 value of 37.1 +/- 2.4 ng mL(-1) (n = 9), a detectio

49 % of the small molecules prepared showed an IC50 value of less than 100 mum, and approximately 25 %

50 The assay shows an IC50 of 4.5 +/- 1.2 ng/mL, with a limit of detection of

51 With an IC50 in the high picomolar range, the apparent affinity

52 inhibitors of alpha-amylase activity with an IC50 of (0.075+/-0.010-0.103+/-0.017) mg/ml, also a mixe

53 ean IC50 of 0.055 ug/mLl and SHIVAD8 with an IC50 of 0.028 ug/mLl.

54 ibition of cell recruitment in vitro with an IC50 of 0.5 nm but demonstrated little efficacy in vario

55 Compound 22a inhibited SphK1 with an IC50 of 2 nM and was more than 100-fold selective for Sp

56 nt at inhibiting chemotaxis in vitro with an IC50 of 21 nm Furthermore, we observed that 1B6 displaye

57 and selective GRK2 inhibitor, 14as, with an IC50 of 30 nM against GRK2 and greater than 230-fold sel

58 synthesized was found to inhibit ACE with an IC50 of 300+/-2microM.

59 740 was also five times more potent, with an IC50 of 5 muM, in a fibroblast-mediated collagen contrac

60 ich is a very potent, dual inhibitor with an IC50 of 67 nM for BRPF2 BD, 8 nM for TAF1 BD2, and 106 n

61 Q-1 reduced tumor cell proliferation with an IC50 of ~1.0 muM and decreased tumor growth rate in mous

62 minantly by hydroxo-species of U(VI) with an IC50 threshold of approximately 90 muM.

63 a potent inhibitor of alpha-amylase with an IC50 value of 0.046+/-0.004mg/ml.

64 hest inhibition was found to be MCS, with an IC50 value of 0.29muM.

65 the highest ACE inhibitory activity, with an IC50 value of 0.54mg/ml, while the SP hydrolysate exhibi

66 Compound 18 (MM-589) binds to WDR5 with an IC50 value of 0.90 nM (Ki value <1 nM) and inhibits the

67 selective irreversible inhibitor 45a with an IC50 value of 1 nM against the EGFR L858R/T790M double m

68 3K4 methyltransferase (HMT) activity with an IC50 value of 12.7 nM.

69 ted DPPH radical scavenging activity with an IC50 value of 20.02+/-0.14muM which was better than asco

70 activity against Leishmania donovani with an IC50 value of 9.22 muM.

71 activity in a dose dependent manner with an IC50 value of about 2mgmL(-1).

72 nhibition of cell proliferation, yielding an IC50 value of 356 +/- 21 nM in neuroblastoma SHSY5Y cell

73 anthocyanin and IC50 value of 1.60mg/ml for tyrosinase inhibitory activi

74 A validation assay was then conducted and IC50 values were determined.

75 strate and inhibitor enzyme kinetics (Km and IC50), (2) its amino acid sequence and (3) its ability t

76 itory activity with IC50=1.1+/-0.1mug/ml and IC50=19.3+/-1.1mug/ml, respectively.

77 XAV939)(5), i.e., IC50 = 100 pM vs TNKS2 and IC50 = 6.5 muM vs PARP1 for 14.

78 und between total phenolic content (TPC) and IC50 for dark coloured varieties.

79 al inhibitory concentration of the antibody (IC50).

80 IC) of 12.5 mug/mL and an Mtb Ag85C apparent IC50 of 8.8 muM.

81 concentration-dependent manner with apparent IC50's equivalent to IC50's on LRRK2-pSer935.

82 he sensitivity of the biosensor, measured as IC50 value, was 1.51U/mL and 0.32U/mL, for anti-TRIM21 a

83 ndeed has a submicromolar potency at ASIC1a (IC50 0.3 muM).

84 ual inhibitors of human SHMT1/2 (biochemical IC50 approximately 10 nM).

85 115 hits for which we determined biochemical IC50, thus identifying four chemical series.

86 tion resulted in compound 2 with biochemical IC50 = 160 nM.

87 s the strongest cytotoxic activity on BT474 (IC50 = 55.5 nM, BRCA2 and TP53 co-mutant) compared to MC

88 The results represented by IC50 values revealed that Huh7 cells had a higher drug r

89 docking scores and experimentally calculated IC50 values.

90 that no direct method exists for calculating IC50 values, we resort to a combination of atomistic mod

91 ry safety and high therapeutic indices (CC50/IC50 > 180), and thus representing potential promising l

92 oximately 2000-fold less active toward CDK1 (IC50 86 muM).

93 73) that exhibited high potency toward CDK2 (IC50 0.044 muM) but was approximately 2000-fold less act

94 n selective cytotoxicity against V-C8 cells (IC50 17 microg/ml) compared to V79 cells (IC50 26 microg

95 sistant A2780Cis human ovarian cancer cells (IC50 74 muM, blue light) with a photocytotoxic index <2,

96 wer concentration than to lung cancer cells (IC50 = 59.1 mug/mL), and L-PTX demonstrated a comparable

97 ntrolled gene transcription in living cells (IC50 = 230 nM), providing the most potent inhibitor of t

98 but they are less cytotoxic on normal cells (IC50 > 100 microM).

99 s (IC50 17 microg/ml) compared to V79 cells (IC50 26 microg/ml).

100 y, led to compound 9b, exhibiting a cellular IC50 for NF-kappaB inhibition of 0.3 muM while retaining

101 kyrase 1 and 2 with biochemical and cellular IC50 values of 29 nM, 6.3 nM and 19 nM, respectively, an

102 HCl] (8) selectively blocked Kv1.1 channels (IC50 approximately 15 muM) recombinantly expressed in ma

103 SY5Y (i.e. both L-type and T-type channels) (IC50 = 8 +/- 0.23 and 10 +/- 0.18 mug/ml, respectively)

104 = 10.6 +/- 1.3 to 1.6 +/- 0.3 muM) and CME (IC50(CME) = 65.9 +/- 7.7 to 3.7 +/- 1.1 mM), which makes

105 ce) showed improved inhibition for collagen (IC50 = 6.7 muM), CRP-XL (IC50 = 53.5 muM), and convulxin

106 han any of its enantiomers S (6c) (collagen, IC50 = 25.3 muM; CRP-XL, IC50 = 181.4 muM; CVX, IC50 = 9

107 uM; CVX, IC50 = 9 muM) and R (6d) (collagen, IC50 = 126.3 muM; CRP-XL, IC50 > 500 muM; CVX, IC50 = 86

108 ion as compared to losartan (LOS) (collagen, IC50 = 10.4 muM; CRP-XL, IC50 = 158 muM; CVX, IC50 = 11

109 igher than the 50% inhibitory concentration (IC50) (11.5 ng/mL).

110 Half maximal inhibitory concentration (IC50) of BA were calculated as 13.93microM and 25.66micr

111 PP-IV half maximal inhibitory concentration (IC50) of H4, a potent sample, was maintained following s

112 with half-maximal inhibitory concentration (IC50) values ranging from 1.03 muM to >1 mM.

113 hibited 50% growth inhibitory concentration (IC50) values that were less than 20 muM in HeLa cells, i

114 ) and half maximal inhibitory concentration (IC50) values.

115 mivir half-maximal inhibitory concentration (IC50), and E119D conferred the highest zanamivir IC50.

116 tion [half maximal inhibitory concentration (IC50): 3.8muM] and ATP synthesis (IC50: 0.9muM), and add

117 ains in vitro (50% inhibitory concentration [IC50] > 5 mug/ml).

118 arum (half maximal inhibitory concentration [IC50] = 1-2 uM), suggesting that BCH070 acts via a novel

119 ing potential (50% inhibitory concentration, IC50 approximately 0.59mg/mL) than commercially availabl

120 P-IV half maximal inhibitory concentrations (IC50) of 87.0+/-3.2 and 93.3+/-8.0microM, respectively.

121 001) half-maximal inhibitory concentrations (IC50) than did donor isolates, and their odds of replica

122 Half-maximal inhibitory concentrations (IC50) were obtained for each drug-material combination,

123 olar half-maximal inhibitory concentrations (IC50).

124 with half-maximal inhibitory concentrations (IC50s) in the 10- to 100-ng/mL range.

125 The 50% inhibitory concentrations (IC50s) were determined.

126 o piperaquine 50% inhibitory concentrations (IC50s), and tested whether these genetic variants are ma

127 P-XL (IC50 = 53.5 muM), and convulxin (CVX) (IC50 = 5.7 muM) mediated platelet aggregation as compare

128 C50 = 10.4 muM; CRP-XL, IC50 = 158 muM; CVX, IC50 = 11 muM) than any of its enantiomers S (6c) (colla

129 50 = 126.3 muM; CRP-XL, IC50 > 500 muM; CVX, IC50 = 86.8 muM).

130 0 = 25.3 muM; CRP-XL, IC50 = 181.4 muM; CVX, IC50 = 9 muM) and R (6d) (collagen, IC50 = 126.3 muM; CR

131 thermore, compound 25 inhibited rat CYP11B1 (IC50 = 2 muM) and showed a high oral bioavailability (F

132 All BODIPYs were nontoxic in the dark (IC50 > 200 muM) and showed low phototoxicity (IC50 > 100

133 of TRAP5a and 5b activity reported to date (IC50 1.3 and 1.8 muM respectively).

134 , IL-8, and MIP-1beta) by monocytes and DCs (IC50 < 1 muM) and prevented DC maturation upon TLR4 acti

135 most active being benzothiazole derivative (IC50 = 0.56 muM).

136 d a significant reduction of the doxorubicin IC50 value.

137 as least sensitive because they showed drug IC50 value greater than the cell panel median and lacked

138 he "standard" inhibitor 1 (XAV939)(5), i.e., IC50 = 100 pM vs TNKS2 and IC50 = 6.5 muM vs PARP1 for 1

139 onstrated a strong radical quenching effect (IC50: 0.48mg/ml).

140 V from black soybean was the most effective (IC50: 0.25mg/mL) against alpha-amylase; Fraction V from

141 The study analyzed the inhibitory effects (IC50) of crude and purified extracts from Maliniak, Ceri

142 nd delphinidin-3-O-glucoside inhibited EGFR (IC50=0.10 and 2.37microM, respectively).

143 , this compound was still not potent enough (IC50 approximately 53 nM) to enter preclinical studies.

144 d dehydrogenase type 1 (11beta-HSD1) enzyme (IC50 3.0 nM) with >10000-fold selectivity over human 11b

145 ion from T4, respectively, with an estimated IC50 of 160 nM; no statistically significant inhibition

146 legal driving limit of 0.08% (w/v) ethanol (IC50 = 0.2% v/v, 34 mM).

147 networks are trained by use of experimental IC50 values collected in the CATNAP database.

148 The concentration inhibition fifty (IC50) for BL, SH, RG on HT-29 and HCT-116 cell prolifera

149 These compounds exhibited GSK3 IC50s in the low nanomolar range and excellent selectivi

150 ess than 100 mum, and approximately 25 % had IC50 values below 1 mum to Mcl-1.

151 roacetamide at the thiophene 2-position, had IC50 of approximately 30 nM, approximately 3.6-fold more

152 phoramidate prodrugs of these compounds have IC50 values in the low micromolar range in Pf lines and

153 d 7G8) P. falciparum strains with 5/6 having IC50 < 100 nM against the NF54 strain.

154 LRRK2-pSer935 HEK293 IC50 data for 22 were consistent with binding to Ala2016

155 representing IKr (CHO cells expressing hERG; IC50=219+/-21 mumol/L) and IKs (CHO cells expressing KCN

156 he growth of HCC cells, although at a higher IC50 as compared with breast cancer cells, likely due to

157 IDPR inhibit CD38-mediated cADPR hydrolysis (IC50 7 muM and 21 microM respectively) with 8-Br-L-cIDPR

158 icromolar inhibition against both dynamin I (IC50 = 10.6 +/- 1.3 to 1.6 +/- 0.3 muM) and CME (IC50(CM

159 otency of ATRA on HCC cell growth, improving IC50 by over 3-fold.

160 pounds displayed a similar decrease (30%) in IC50 for inhibition of [(3)H]DA uptake by cocaine in WT

161 ional options in achieving relative error in IC50 within 5-fold for test cases and 20-fold for protei

162 d susceptible and 2 had a slight increase in IC50 (3- to 5-fold change).

163 rug-material combination, and an increase in IC50 of approximately 4.3x was observed in PDMS devices

164 ToF-SIMS data showed the bias observed in IC50 values found in PDMS devices was directly related t

165 e retaining a potent EGFR kinase inhibition (IC50 = 60 nM).

166 20%), ROS (32%) and lipoxygenase inhibition (IC50=31.24muM) compared to FS.

167 hits into potent small molecule inhibitors (IC50 < 300 nM).

168 The most potent inhibitors (IC50 </= 50 nM) significantly decreased viability, clono

169 e IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM) and favorable pharmacokinetic and toxicol

170 IPG phospholipase activity and determine its IC50.

171 e and a plasma concentration higher than its IC50 for over 7 h.

172 ted gastrointestinal digestion (SGID, DPP-IV IC50=0.60+/-0.06vs.

173 ty was found with the amino acid Tyr (DPP-IV IC50=75.15+/-0.84muM).

174 ) and IKs (CHO cells expressing KCNQ1+KCNE1; IC50=184+/-12 mumol/L), whereas azithromycin suppressed

175 ed a comparable toxicity in both cell lines (IC50 = 31.8 and 33.7 mug/mL).

176 alpha-amylase, alpha-glucosidase and lipase (IC50: 0.38mg/mL, 0.87mug/mL and 15mug/mL, respectively).

177 Quantitative log IC50 was predicted with an average validated R2 of 0.355

178 Bictegravir had a lower IC50 than the other INSTIs on those HIV-2 isolates beari

179 ibitors in that they demonstrated the lowest IC50 values (2 muM) ever observed among all indole-based

180 inhibition zone diameter, the half maximal (IC50) and the minimal (MIC) inhibitory concentrations.

181 BRCA2 and TP53 co-mutant) compared to MCF7 (IC50 = 7.7 muM, both BRCA2 and TP53 wild type) and MDA-M

182 a 42-pseudovirus panel with a geometric mean IC50 of 0.055 ug/mLl and SHIVAD8 with an IC50 of 0.028 u

183 falciparum laboratory-adapted strains (mean IC50 32 nM), Ugandan field isolates (mean ex vivo IC50 6

184 lade isolates (n = 117) with a potent median IC50 of 0.028 mug ml(-1).

185 Axl receptor activation with low micromolar IC50s in cell-based reporter assays, inhibit Gas6-induci

186 fractions of CO7 cultivar of foxtail millet (IC50, 22.37 and 57.26microg/ml) and CO4 cultivar of litt

187 icrog/ml) and CO4 cultivar of little millet (IC50, 18.97 and 55.69microg/ml) displayed strong inhibit

188 ys acceptable antituberculosis activity (Mtb IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patie

189 a(++) currents (rabbit ventricular myocytes, IC50=66.5+/-4 mumol/L) and IK1 (HEK cells expressing Kir

190 46, 49, and 50 showed single-digit nanomolar IC50 values for in vitro inhibition of KDM1A, with high

191 s a result, compound 12 showed low nanomolar IC50 for both targets.

192 most interesting compound 9 showed nanomolar IC50 values for both proteins, membrane permeability, an

193 igh in vitro activity against C. neoformans (IC50 = 0.35 mug/mL, MIC = MFC = 0.63 mug/mL) with a sele

194 1g-i revealed low nM IC50 values for HDAC6 with up to 15-fold preference over

195 f nitrate with strong pi affinity nullified (IC50 = 2.2 mM) the responsiveness of anion-pi catalysts

196 ,3'-T2 formation from rT3 was also observed (IC50 approximately 100 nM).

197 Compounds 11 and 12 showed the values of IC50 at 11.9 and 17.2 muM against neglected Chagas' dise

198 itaxel was toxic to cell of neuronal origin (IC50 = 18.4 mug/mL) at a lower concentration than to lun

199 606120 is a selective antagonist for P2X7Rs (IC50 of 10 nM) and ineffective at the P2X1R (at 10 muM).

200 Paclitaxel IC50 in PC3 and PC3-TXR cells was 55.6 and 2,580 nmol/L,

201 d resistant Plasmodium falciparum parasites (IC50 1-5 nM) as well as against gametocytes.

202 nst Plasmodium falciparum malaria parasites (IC50 approximately 1 muM).

203 tivity (10-14mumol Trolox eq./mumol peptide; IC50=11-21muM).

204 due to accumulation of hydrophobic peptides (IC50 between 12 and 21mg/l).

205 els exhibited more potent photocytotoxicity (IC50 3 muM, blue light) with a photocytotoxic index >5.

206 C50 > 200 muM) and showed low phototoxicity (IC50 > 100 muM, 1.5 J/cm(2)) toward human HEp2 cells.

207 me 14 also associate with raised piperaquine IC50s.

208 Pitavastatin (IC50 = 0.6-14 muM), zoledronic acid (IC50 = 21-57 muM),

209 The high potency (IC50 of 31 nM [MMP-10] and 5 nM [MMP-13]) and selectivit

210 The highly potent (IC50 = 10 nM) inhibitor N-(3,4-dimethoxyphenyl)ethyl ami

211 from black turtle bean was the most potent (IC50: 0.25mug/mL) against alpha-glucosidase; Fraction IV

212 5-lipoxygenase (5-LOX) inhibition potential (IC50 0.76-0.92mg/mL) of the polyketides in consonant wit

213 rom black turtle bean was the most powerful (IC50: 76mug/mL) against lipase.

214 n wild-type RTD-1 in inhibiting LF protease (IC50 = 43 +/- 3 nM, Ki = 18 +/- 1 nM).

215 itor of anthrax lethal factor (LF) protease (IC50 = 390 +/- 20 nM, Ki = 365 +/- 20 nM) and a weak inh

216 agement was demonstrated, with LRRK2-pSer935 IC50 values for 22 in mouse brain and kidney being 1.3 a

217 inhibits the JNK3 in the subnanomolar range (IC50 = 0.3 nM), shows high metabolic stability in human

218 e 22.4-40.6muM) and myeloperoxidase release (IC50 in the range 22.2-32.2muM) from stimulated human ne

219 aused by large fractions of VRC01-resistant (IC50>50 mug/mL) circulating strains or rather a global r

220 s as potent blockers of TGF-beta1 responses (IC50 50 nM), Snail1 expression, and collagen deposition

221 ther characterization of ciproxifan revealed IC50 values in a micromolar concentration range for huma

222 dronic acid (IC50 = 21-57 muM), risedronate (IC50 > 100 muM) or GGTI-2133 (IC50 > 25 muM) inhibited t

223 ith excellent recovery and high sensitivity, IC50 = 0.28 mug/L, with a limit of detection that is wel

224 ere considerably weaker inhibitors of SGLT1 (IC50 = 10-19 muM).

225 The most potent inhibitors of SGLT2 (IC50 = 9-23 nM) were considerably weaker inhibitors of S

226 The three most potent compounds 1g-i showed IC50 values in the low muM and sub-muM range.

227 ound displays nanomolar in vitro and in situ IC50 values and fully inhibits ABHD3 activity in human c

228 Exposure of HeLa cells to Cu(PyBD).SO4 (IC50 = 10 muM) results in a G2/M arrest compared with un

229 ane permeabilized), BeauIII inhibited SOAT1 (IC50, 1.8 microM) and SOAT2 (5.9 microM).

230 lized), BeauIII selectively inhibited SOAT1 (IC50; 5.0 microM (SOAT1) vs >90 microM (SOAT2)), while i

231 t the production of reactive oxygen species (IC50 in the range 22.4-40.6muM) and myeloperoxidase rele

232 ch inhibited the enzyme with a submicromolar IC50 (0.162 muM), capable of inhibiting the target in ce

233 entration (IC50): 3.8muM] and ATP synthesis (IC50: 0.9muM), and additional findings supported inhibit

234 Compound 1 displayed a TarO IC50 of 125 nM in an enzyme assay and possessed very hig

235 The IC50 value equal to 70mM was very high compared to usual

236 The IC50 value of 0.002 against E. ictaluri indicates approx

237 The IC50 values for compounds 1-3 are within nanomolar range

238 more potent than its congener GL331 and the IC50 values are from 0.34 +/- 0.21 to 3.54 +/- 0.54 micr

239 ure for envisioned clinical application, the IC50 of MEAN was not significantly changed in several dr

240 lowing knockdown of MARCKS in RCC cells, the IC50 of the multikinase inhibitor regorafenib was reduce

241 ped a computational approach to estimate the IC50 and use it to determine the antibody breadth.

242 stable EVG concentrations that exceeded the IC50 for wild-type HIV, suggesting that EVG achieves the

243 Importantly, the IC50 for NSAH is within twofold of gemcitabine for growt

244 Under hypoxic conditions, a decrease in the IC50 of MTX and MTX-loaded MSNR was observed when compar

245 up, there were no significant changes in the IC50(palmitate)f (19 +/- 2 compared with 24 +/- 3 muIU/m

246 Neural Network) to predict the value of the IC50 (by regression), or if the antibody binds or not to

247 We show that estimates of the IC50 (employing a novel specific and efficient assay tha

248 s reduced cell proliferation and reduced the IC50 inhibitory concentration of chemotherapeutic drugs

249 leukemic cytokine secretion and reduced the IC50 of chemotherapeutic drug treatments in AML cells.

250 of PARP inhibitor >1000-fold higher than the IC50 were required to ablate both ADP-ribosylation and X

251 ichotomous resistance outcome of whether the IC50 neutralization titer of VRC01 for a given Env pseud

252 Also, the IC50s for RU.365, RU.332 and RU.521 within panel h were

253 the rationale behind the disparity in their IC50.

254 nt manner with apparent IC50's equivalent to IC50's on LRRK2-pSer935.

255 han commercially available alpha-tocopherol (IC50 0.63mg/mL).

256 potent than cocaine at inhibiting DA uptake (IC50 = 107 nM).

257 t potent compound, has an excellent in vitro IC50 (0.056 nM) and improved aqueous solubility as well

258 and up to 50,000 times the reported in vitro IC50 value.

259 In vitro IC50 values were 11-48 ng/mL in HER2 3+ SK-BR-3 and KPL-

260 ound to be extremely potent with an in vitro IC50 ~ 100x lower than folate SMDCs constructed with var

261 t disrupt the EthR-DNA interaction in vitro (IC50 =460-610 mum) and bind to the hydrophobic channel o

262 32 nM), Ugandan field isolates (mean ex vivo IC50 64 nM), and murine P. berghei and P. falciparum inf

263 t T. daenensis-3 (IC50=273.36), T. vulgaris (IC50=289.3), and T. fedtschenkoi-3 (IC50=339.22) possess

264 losis activity (Mtb IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM

265 tumors, is a bona fide PORCN inhibitor whose IC50 for inhibition of Wnt fatty acylation in vitro clos

266 ibits JAK1 and HDACs 1, 2, 3, 6, and 10 with IC50 values of less than 20 nM, is <100 nM potent agains

267 yl)-5-fluoro-1H-benzo [d]imidazole (42) with IC50 values of 44 and 50 nM, respectively.

268 owed the best ACE-inhibitory activities with IC50 values of 53.31 and 75.05microg/ml, respectively.

269 , 1b displayed full antagonist activity with IC50 = 6 +/- 2 muM.

270 hibit an outstanding antiviral activity with IC50 in the sub-nanomolar range!

271 nd strongly inhibit telomerase activity with IC50 of 600 nM.

272 e and alpha-amylase inhibitory activity with IC50=1.1+/-0.1mug/ml and IC50=19.3+/-1.1mug/ml, respecti

273 he greatest antiproliferative activity, with IC50 values of 0.35-4.6 nM (4g) and 0.5-20.2 nM (4i), wh

274 erial and human salivary alpha-amylases with IC50 values of 0.11 and 0.04mumol, respectively, whereas

275 lenging triple mutant L858R/T790M/C797S with IC50 values in the low nanomolar range.

276 activity against MCF-7 and HL-60 cells with IC50 of 6.13 +/- 0.64 and 4.43 +/- 0.35, respectively.

277 liferative effects against cancer cells with IC50 range of 4.43 +/- 0.35 to 49.63 +/- 3.59 microM, bu

278 l extraction methods (10.93mg/g content with IC50 of 2.81mg/ml).

279 histamine release were dose dependent, with IC50 values ranging between 0.001 and 0.5 mumol/L, and t

280 RSM-932A and MN58b that were discovered with IC50 of 0.5 and 150 muM, respectively, and were shown to

281 activity against Plasmodium falciparum with IC50 values of 1.84, 8.36, and 6.95 muM, respectively.

282 2C notably inhibited alpha-glucosidase, with IC50=9.89 and 8.05mug/mL, respectively.

283 well as significant inhibition of HDAC6 with IC50 values in the submicromolar concentration range.

284 entified as jack bean urease inhibitors with IC50 values of 2.8 and 5.0mM, respectively.

285 ds 1 and 3 strongly inhibited NF-kappaB with IC50 values of 7.1 and 1.5 muM, respectively.

286 accumulation in small intestinal loops, with IC50 down to 0.1 mg/kg.

287 Five fragments inhibited MTH1 with IC50 values ranging from 6 to 79 muM.

288 y to inhibit the growth of the parasite with IC50 values in submicromolar range.

289 -3-gallate, and theaflavin inhibited PL with IC50 of 1.9, 4.2, 3.0, and >10mumol/L.

290 A topoisomerase I inhibition properties with IC50 values <5.0 muM.

291 native membranes or in proteoliposomes, with IC50 values in the 10-40 nm range.

292 BP1 and SMB methylation and cell stasis with IC50 values in the nanomolar range.

293 ble enterotoxin of E. coli (STa toxin), with IC50 down to approximately 5 nM.

294 hich inhibited IMPalpha/beta1:C binding with IC50s as low as 5 microM.

295 ruses were susceptible to the 5 INSTIs, with IC50s in the nanomolar range.

296 ition for collagen (IC50 = 6.7 muM), CRP-XL (IC50 = 53.5 muM), and convulxin (CVX) (IC50 = 5.7 muM) m

297 R (6d) (collagen, IC50 = 126.3 muM; CRP-XL, IC50 > 500 muM; CVX, IC50 = 86.8 muM).

298 an (LOS) (collagen, IC50 = 10.4 muM; CRP-XL, IC50 = 158 muM; CVX, IC50 = 11 muM) than any of its enan

299 s S (6c) (collagen, IC50 = 25.3 muM; CRP-XL, IC50 = 181.4 muM; CVX, IC50 = 9 muM) and R (6d) (collage

300 ), and E119D conferred the highest zanamivir IC50.